Why Human Error Won’t Go Away in Pharma Manufacturing

And What We Must Do About It

Despite billions invested in automation, digital systems, and process controls, human error remains one of the most persistent—and costly—sources of deviation in pharmaceutical manufacturing. From aseptic contamination to documentation mistakes, from equipment misconfiguration to data integrity lapses, the errors often point not to bad actors but to broken systems, weak training, and cultural blind spots. To truly address human error, we have to go beyond blaming the individual and ask: why is the error occurring in the first place?

One of the most foundational reasons is inadequate training. Many operators receive procedure-based instruction that teaches them what to do, but not why it matters. Without the deeper context of microbiology, GMP principles, and regulatory risk, employees may follow instructions superficially—until something unexpected happens. That’s when errors creep in: not because of negligence, but because the system failed to build true understanding.

Closely related is the problem of procedural complexity. In many facilities, SOPs are bloated, contradictory, or poorly written. An operator may be expected to follow dozens of pages of detailed instructions under time pressure or while suited up in uncomfortable PPE. When those instructions lack clarity or logic, deviations become almost inevitable. And when processes rely on tribal knowledge or unwritten “workarounds,” it’s no longer a question of if someone will make a mistake, but when.

Another factor is the pressure to perform. Whether driven by aggressive production timelines, limited staffing, or cultural norms that value speed over diligence, operators often feel compelled to cut corners or keep going despite uncertainty. The fear of being blamed or written up for asking questions creates a dangerous silence—one that prevents errors from being caught before they become critical.

Cognitive fatigue and environmental stressors also play a major role. Long shifts, rotating schedules, and sterile environments all create conditions where mental focus is tested over time. In aseptic operations, a single lapse in behavior—touching a sterile surface, breaking airflow—can ruin an entire batch. Yet expecting perfection under such strain, without adequate support and reinforcement, sets teams up for failure.

Then there is the illusion of compliance. In too many organizations, checklists are completed because they must be—not because they’re meaningful. “Good documentation practices” may exist on paper, but the system subtly encourages pencil-whipping, backdating, or blindly initialing boxes. These aren’t ethical lapses as much as cultural signals that accuracy matters less than appearances.

Another root cause is poor change management. When a process changes, when a new system is introduced, or when a new piece of equipment is installed, people often aren’t properly retrained. Old habits persist, new instructions are misunderstood, and transitional errors spike. It’s a reminder that change isn’t just a technical event—it’s a human one.

Hierarchy and siloed communication also contribute. Frontline operators may observe process weaknesses but lack the authority—or the psychological safety—to report them. Meanwhile, management may design controls or investigations without involving those who do the work. This disconnect creates blind spots where risk festers.

We also must consider the impact of inadequate root cause investigations. Too often, companies stop at “operator error” without digging deeper. Was the lighting poor? Was the gowning procedure confusing? Was the workload excessive? When we fail to uncover true systemic causes, we allow those same errors to recur.

Digital systems, while transformative, can also introduce new opportunities for error if poorly designed. User interfaces that are counterintuitive, systems that lack validation controls, or training that focuses on keystrokes rather than outcomes can lead to data-entry mistakes, missed alarms, or critical overrides that compromise product quality.

Finally, and perhaps most insidiously, is the lack of a true quality culture. If employees feel their voices don’t matter, if investigations feel punitive, or if quality is seen as a barrier rather than a shared value, then human error becomes a symptom of a much larger illness. True quality culture is built when people feel ownership—not fear—over the work they do.

In the end, human error is not simply a behavioral issue; it’s a systems issue. It’s about how we train, how we communicate, how we lead, and how we design environments where people can succeed. Reducing error doesn’t mean eliminating humans. It means designing systems that respect human nature—and support it with precision, purpose, and trust.


QxP Vice President Christine Feaster is a 20+ year veteran in pharma quality assurance. Prior to joining QxP, Christine was a vice president of U.S. Pharmacopeia.

Despite billions invested in automation, digital systems, and process controls, human error remains one of the most persistent—and costly—sources of deviation in pharmaceutical manufacturing. From aseptic contamination to documentation mistakes, from equipment misconfiguration to data integrity lapses, the errors often point not to bad actors but to broken systems, weak training, and cultural blind spots. To truly address human error, we have to go beyond blaming the individual and ask: why is the error occurring in the first place?

One of the most foundational reasons is inadequate training. Many operators receive procedure-based instruction that teaches them what to do, but not why it matters. Without the deeper context of microbiology, GMP principles, and regulatory risk, employees may follow instructions superficially—until something unexpected happens. That’s when errors creep in: not because of negligence, but because the system failed to build true understanding.

Closely related is the problem of procedural complexity. In many facilities, SOPs are bloated, contradictory, or poorly written. An operator may be expected to follow dozens of pages of detailed instructions under time pressure or while suited up in uncomfortable PPE. When those instructions lack clarity or logic, deviations become almost inevitable. And when processes rely on tribal knowledge or unwritten “workarounds,” it’s no longer a question of if someone will make a mistake, but when.

Another factor is the pressure to perform. Whether driven by aggressive production timelines, limited staffing, or cultural norms that value speed over diligence, operators often feel compelled to cut corners or keep going despite uncertainty. The fear of being blamed or written up for asking questions creates a dangerous silence—one that prevents errors from being caught before they become critical.

Cognitive fatigue and environmental stressors also play a major role. Long shifts, rotating schedules, and sterile environments all create conditions where mental focus is tested over time. In aseptic operations, a single lapse in behavior—touching a sterile surface, breaking airflow—can ruin an entire batch. Yet expecting perfection under such strain, without adequate support and reinforcement, sets teams up for failure.

Then there is the illusion of compliance. In too many organizations, checklists are completed because they must be—not because they’re meaningful. “Good documentation practices” may exist on paper, but the system subtly encourages pencil-whipping, backdating, or blindly initialing boxes. These aren’t ethical lapses as much as cultural signals that accuracy matters less than appearances.

Another root cause is poor change management. When a process changes, when a new system is introduced, or when a new piece of equipment is installed, people often aren’t properly retrained. Old habits persist, new instructions are misunderstood, and transitional errors spike. It’s a reminder that change isn’t just a technical event—it’s a human one.

Hierarchy and siloed communication also contribute. Frontline operators may observe process weaknesses but lack the authority—or the psychological safety—to report them. Meanwhile, management may design controls or investigations without involving those who do the work. This disconnect creates blind spots where risk festers.

We also must consider the impact of inadequate root cause investigations. Too often, companies stop at “operator error” without digging deeper. Was the lighting poor? Was the gowning procedure confusing? Was the workload excessive? When we fail to uncover true systemic causes, we allow those same errors to recur.

Digital systems, while transformative, can also introduce new opportunities for error if poorly designed. User interfaces that are counterintuitive, systems that lack validation controls, or training that focuses on keystrokes rather than outcomes can lead to data-entry mistakes, missed alarms, or critical overrides that compromise product quality.

Finally, and perhaps most insidiously, is the lack of a true quality culture. If employees feel their voices don’t matter, if investigations feel punitive, or if quality is seen as a barrier rather than a shared value, then human error becomes a symptom of a much larger illness. True quality culture is built when people feel ownership—not fear—over the work they do.

In the end, human error is not simply a behavioral issue; it’s a systems issue. It’s about how we train, how we communicate, how we lead, and how we design environments where people can succeed. Reducing error doesn’t mean eliminating humans. It means designing systems that respect human nature—and support it with precision, purpose, and trust.


QxP Vice President Christine Feaster is a 20+ year veteran in pharma quality assurance. Prior to joining QxP, Christine was a vice president of U.S. Pharmacopeia.

What keeps the CDMO QA Head up at Night

Drew Cullinane
January 22, 2026

Digital Twins and Human-Machine Collaboration in Biopharma Operations

Christine Feaster
January 9, 2026

Regulatory Convergence in Biosimilar Manufacturing

Christine Feaster
January 7, 2026

The Top 5 Data Integrity Citations in Pharma

Christine Feaster
December 16, 2025

Workforce, Digitalization & Onshoring

Christine Feaster
December 11, 2025

Data Integrity in the Age of Smart Manufacturing

Christine Feaster
December 11, 2025

Speeding the Shift and Understanding the GMPs

Christine Feaster
December 5, 2025

Regulatory Readiness for Advanced Modalities

Christine Feaster
December 2, 2025

Regulatory Readiness for Advanced Modalities

Christine Feaster
November 20, 2025

Why Tech Transfer Fails at CDMOs

Drew Cullinane
November 19, 2025

The QxP Approach Makes the Difference

Elizabeth Thomae
November 18, 2025

America's Biomanufacturing Powerhouse

Christine Feaster
November 12, 2025

Client Retention Starts on Day 1

Drew Cullinane
November 6, 2025

From Executive Order to Execution

Christine Feaster
October 28, 2025

Regulatory and New Technology in the CDMO space

Christine Feaster
October 28, 2025

Rebuilding Where It Matters

Christine Feaster
October 20, 2025

Where Did Everyone Go?

Christine Feaster
October 14, 2025

How QxP Helps Companies Navigate FDA Complete Response Letters (CRLs)

Christine Feaster
October 3, 2025

Inspection Readiness as Competitive Advantage

Christine Feaster
October 1, 2025

Growing by Acquisition is (not) like shopping at IKEA

Mark Roache
August 6, 2025

Beyond the Audit

Christine Feaster
July 30, 2025

Threat or Promise?

Mark Roache
July 22, 2025

Why Education and Training Are Crucial for Indian Pharma

Christine Feaster
July 21, 2025

Strategic Support

Christine Feaster
July 11, 2025

Uncovering Hidden Risks and Value

Christine Feaster
July 7, 2025

Strategic role of Quality Executive Partners in FDA Pre-Meetings for Foreign and Domestic Manufacturers

Christine Feaster
July 3, 2025

The High-Performing Team

Mark Roache
July 2, 2025

Another failed CAPA

Mark Roache
June 19, 2025

Mastering the Molecular Maze

Christine Feaster
June 17, 2025

ADVANCING ONSHORING: Strengthening U.S. Pharma Through Innovation and Oversight

Mark Roache
Glenn Barbrey
May 27, 2025

Why You Need a Consultancy During Uncertain Times

Christine Feaster
May 23, 2025

Building Supplier Resilience Amid Onshoring and Tariff Risks

Christine Feaster
May 19, 2025

Virtual Reality - Reshaping Education Across the Pharmaceutical Landscape.

Christine Feaster
May 14, 2025

Transferring Success: Best Practices for Pharma Onshoring

Christine Feaster
May 6, 2025

Quality Metrics in Pharma

Christine Feaster
May 2, 2025

The Value Of Quality

Mark Roache
May 2, 2025

From CRL to Approval: QxP Navigates FDA Feedback with Timeliness and Precision

Christine Feaster
April 24, 2025

Training for Impact and Excellence

Sarah Boynton
April 15, 2025

Deviation and OOS Investigations in Pharmaceutical Manufacturing

Tamer Helmy, PhD
April 10, 2025

Is Your Contamination Control Strategy Delivering What It Should?

Christine Feaster
April 9, 2025

The Hallmarks of a Successful Pharma Consultancy

Christine Feaster
January 14, 2025

Pharmaceutical Predictions for 2025

Christine Feaster
December 11, 2024

The Crucial Nexus: Data Integrity in Pharmaceutical Manufacturing

Christine Feaster
May 17, 2024

Pharmaceutical Industry Trends for 2024 So Far

Christine Feaster
April 24, 2024

Decoding the Technical Transfer Process in Biotech Manufacturing

Sarah Boynton
April 23, 2024

Quality Executive Partners - IACET Accreditation

Ken Mead
April 9, 2024

Coaching and Correcting: A Focus on Behavior Over Blame

Sarah Boynton
November 1, 2023

The Importance of Roles and Responsibilities in Biotech Manufacturing & Human Error Prevention

Sarah Boynton
October 26, 2023

Remote cGMP Inspections and AI in Drug Manufacturing

Michelle Fishburne
October 11, 2023

4 Best Practices for Effective Investigation into Deviations

Sarah Boynton
September 19, 2023

The Art of Viral Vector Manufacturing: 4 Essential Controls to Prevent Cross-Contamination

Sarah Boynton
September 13, 2023

Practicing Risk Acceptance

Mark Roache
August 28, 2023

Annex 1 – Can we all take a deep breath now?

Vanessa Figueroa
August 24, 2023

In Cell and Gene, Good Science is Necessary, But Not Sufficient

Mark Roache
August 21, 2023

6 Ways To Achieve Manufacturing Audit And Inspection Readiness

Sarah Boynton
August 14, 2023

Experience is What You Get Just After You Needed It, Part 1

Mark Roache
August 10, 2023

Experience is What You Get Just After You Needed It, Part 2

Mark Roache
August 10, 2023

Sterility Assurance Matters to This ONE

Greg Gibb
August 8, 2023

Enhancing Quality and Safety: 3 Essential Human Error Prevention Tools for cGMP Manufacturing

Sarah Boynton
August 3, 2023

Asia-Pacific Happenings: Samsung Bioepis Implements QxP Virtuosi®

Michelle Fishburne
August 2, 2023

CDMOs – Selecting the Right One for Each Manufacturing Stage

Christine Feaster
July 24, 2023

3 Types of Human Error and Potential CAPAs to Prevent Them

Sarah Boynton
July 20, 2023

Drug Shortages: Causes & Solutions

Christine Feaster
July 10, 2023

The 5 Questions You Need to Ask After a Human Error Event Occurs

Sarah Boynton
July 5, 2023

Understanding How Adults Learn

Mike Levitt
June 30, 2023

Annex 1 and Ensuring Filling Technologies Fit the Need

Natasha Howard
June 21, 2023

How to Solve Pharma’s Skilled Workforce Deficit

Jeff Roy
June 20, 2023

ChatGPT Told Me AI is “Imperative” in Pharma Manufacturing

No items found.
June 18, 2023

Get Ready: FDORA’s Unannounced Foreign Inspection Pilot Program is On!

Crystal Mersh
June 6, 2023

Nitrosamines Impurity Challenges

Christine Feaster
June 2, 2023

All You Need to Know About Contamination Control Strategies, Parts 1 and 2

No items found.
June 1, 2023

When is ISO 8 Not ISO 8?

Bob Ferer
May 30, 2023

Cost Of Quality: Worth Every Cent In Bio/Pharmaceutical Manufacturing

Crystal Mersh
May 24, 2023

Pharmaceutical Quality is NOT a Spectator Sport

Mike Levitt
May 22, 2023

The Six Keys for Effective Deviation Investigators

Mike Levitt
May 18, 2023

There Has to be a Better Way to Train

Tyler DeWitt, Ph.D.
May 15, 2023

Cell and Gene: Article Series on CGT’s Key Drivers

Mark Roache
May 8, 2023

Bacterial Endotoxin Testing is on the Move

Christine Feaster
May 5, 2023

Top 20 Pharma Company Chooses QxP Virtuosi® Platform

Vanessa Figueroa
May 3, 2023

Crystal Clear: Controls Are Not Enough

Crystal Mersh
April 22, 2023

Myth #2: Proactively Remediating Bad Inspection Outcomes: What’s the benefit?

Brian Duncan
April 20, 2023

Myth #1: Complying with Regulations and Product Specifications

Brian Duncan
April 20, 2023

Is it Time to Outsource Internal Auditing?

Mike Levitt
April 18, 2023

Quality is Number One, Even When Trying to Address Supply Chain Issues

Christine Feaster
April 14, 2023

Don’t Be a Daredevil When Retrofitting Your Facility, Part 1

Bob Ferer
April 10, 2023

Don’t Be a Daredevil When Retrofitting Your Facility, Part 2

Bob Ferer
April 10, 2023